Drug Profile
Research programme: somatostatin type 2 receptor antagonists - Zucara Therapeutics
Alternative Names: PRL-2903Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Tulane University; University of Toronto; York University
- Developer Zucara Therapeutics
- Class Antihypoglycaemics; Peptides
- Mechanism of Action Somatostatin receptor 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hypoglycaemia
Most Recent Events
- 12 Jun 2020 Preclinical trials in Hypoglycaemia in Canada (Intraperitoneal)
- 12 Jun 2020 Preclinical pharmacokinetics and pharmacodynamics data presented at the 80th Annual Scientific Sessions of the American Diabetes Association (ADA-2020)
- 12 Jun 2020 Interim pharmacodynamics data from preclinical trial in Hypoglycaemia presented at the American Diabetes Association (ADA-2020)